All In Biotech

Drug Trial Radar · NCT06630260

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

A Phase 1/2 Trial of the Doublet Combination of Avutometinib and Defactinib and as a Triplet in Combination With Temozolomide in Patients With High Grade Malignant Brain Tumours Within the 5G Platform

Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

182

Planned (sponsor's estimate)

Start

Nov 15, 2024

Primary completion

Sep 30, 2029

Study completion Sep 30, 2030

Sponsor

Lead sponsor
Institute of Cancer Research, United KingdomAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Minderoo Foundation; Verastem, Inc.; Royal Marsden NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cancer Research UK; University of Cambridge
First posted
Oct 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Health services research
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to evaluate the safety and tolerability of avutometinib and defactinib and to determine the preliminary antitumour activity of avutometinib and defactinib administered at the recommended Phase 2 dose (RP2D). In the Phase 1b of this study parallel biomarker defined arms will be opened, initially in the relapsed GMB setting, enrolling 12 patients onto each arm. These patients will be treated with avutometinib and defactinib double therapy. Avutometinib will be administered orally at 3.2mg twice a week (e.g., on Monday / Thursday or Tuesday / Friday) with or without a meal. The total weekly dose of avutometinib is 6.4mg. Defactinib will be administered orally, at 200mg, twice a day within 30 min after a meal. The total daily dose of defactinib is 400mg. Once a treatment in any biomarker arm has met the "GO" decision (≥3 successes/12 patients) for relapsed GBM in Phase 1b, that arm can progress to Phase 2. The primary objective of Phase 2 is to determine the antitumour activity of investigational agents administered at the RP2D in patients with molecularly defined malignant brain tumours.

Conditions

  • Glioblastoma Multiforme (GBM)
  • Glioblastoma Multiform (Grade IV Astrocytoma)
  • Diffuse Hemispheric Glioma, H3 G34-Mutant
  • Malignant Primary Gliomas

Interventions

  • AvutometinibDrug

    Supplied as 0.8mg capsules.

  • DefactinibDrug

    Supplied as 200mg tablets.

  • TemozolomideDrug

    Temozolomide will be supplied as 5, 20, 100, 140, 180 or 250 mg hard capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b - To evaluate the safety and tolerability of investigational agent in patients with malignant brain tumoursTime frame: 12 months
  2. Phase 1b - To determine the preliminary antitumour activity of the investigational agent administered at the RP2D in patients with molecularly defined malignant brain tumoursTime frame: 12 months
  3. Phase 2 - To determine the antitumour activity of investigational agent administered at the RP2D in patients with molecularly defined malignant brain tumoursTime frame: 9 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Cambridge University Hospitals

    Cambridge, United Kingdom · Recruiting

  • The Royal Marsden Hospital - Drug Development Unit

    Sutton, United Kingdom · Recruiting

  • The Royal Marsden Hospital - Neuro-Oncology Unit

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.